Zacks Investment Research lowered shares of Fibrocell Science Inc. (NASDAQ:FCSC) from a buy rating to a hold rating in a research report released on Tuesday.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Separately, Canaccord Genuity reaffirmed a buy rating and set a $1.50 price objective on shares of Fibrocell Science in a research note on Sunday, August 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $4.65.

Fibrocell Science (NASDAQ:FCSC) traded up 1.5444% during mid-day trading on Tuesday, reaching $0.7101. 166,397 shares of the company’s stock were exchanged. Fibrocell Science has a 52 week low of $0.52 and a 52 week high of $6.18. The company’s market capitalization is $31.17 million. The company’s 50 day moving average price is $0.67 and its 200-day moving average price is $1.15.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.10. Fibrocell Science had a negative net margin of 7,362.25% and a negative return on equity of 215.38%. On average, equities research analysts expect that Fibrocell Science will post ($0.35) earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in FCSC. Janney Montgomery Scott LLC boosted its position in Fibrocell Science by 209.1% in the second quarter. Janney Montgomery Scott LLC now owns 345,864 shares of the company’s stock worth $398,000 after buying an additional 233,982 shares in the last quarter. Oxford Asset Management boosted its position in Fibrocell Science by 60.2% in the second quarter. Oxford Asset Management now owns 313,959 shares of the company’s stock worth $361,000 after buying an additional 118,007 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Fibrocell Science by 31.4% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 250,803 shares of the company’s stock worth $288,000 after buying an additional 59,926 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in Fibrocell Science during the second quarter worth $111,000. Hedge funds and other institutional investors own 61.64% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

5 Day Chart for NASDAQ:FCSC

Receive News & Stock Ratings for Fibrocell Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc. and related stocks with our FREE daily email newsletter.